Correlation Between Allarity Therapeutics and Revelation Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Allarity Therapeutics and Revelation Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Allarity Therapeutics and Revelation Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Allarity Therapeutics and Revelation Biosciences, you can compare the effects of market volatilities on Allarity Therapeutics and Revelation Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Allarity Therapeutics with a short position of Revelation Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Allarity Therapeutics and Revelation Biosciences.

Diversification Opportunities for Allarity Therapeutics and Revelation Biosciences

0.69
  Correlation Coefficient

Poor diversification

The 3 months correlation between Allarity and Revelation is 0.69. Overlapping area represents the amount of risk that can be diversified away by holding Allarity Therapeutics and Revelation Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Revelation Biosciences and Allarity Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Allarity Therapeutics are associated (or correlated) with Revelation Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Revelation Biosciences has no effect on the direction of Allarity Therapeutics i.e., Allarity Therapeutics and Revelation Biosciences go up and down completely randomly.

Pair Corralation between Allarity Therapeutics and Revelation Biosciences

Given the investment horizon of 90 days Allarity Therapeutics is expected to under-perform the Revelation Biosciences. In addition to that, Allarity Therapeutics is 1.35 times more volatile than Revelation Biosciences. It trades about -0.29 of its total potential returns per unit of risk. Revelation Biosciences is currently generating about -0.07 per unit of volatility. If you would invest  106.00  in Revelation Biosciences on August 31, 2024 and sell it today you would lose (30.00) from holding Revelation Biosciences or give up 28.3% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Allarity Therapeutics  vs.  Revelation Biosciences

 Performance 
       Timeline  
Allarity Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Allarity Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's essential indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
Revelation Biosciences 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Revelation Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Allarity Therapeutics and Revelation Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Allarity Therapeutics and Revelation Biosciences

The main advantage of trading using opposite Allarity Therapeutics and Revelation Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Allarity Therapeutics position performs unexpectedly, Revelation Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Revelation Biosciences will offset losses from the drop in Revelation Biosciences' long position.
The idea behind Allarity Therapeutics and Revelation Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years